10.03.2020 Biofrontera AG  DE0006046113

DGAP-News: Biofrontera AG: European Commission approves use of Ameluz(R) for the treatment of actinic keratosis on extremities and trunk/neck


 

DGAP-News: Biofrontera AG / Key word(s): Miscellaneous
Biofrontera AG: European Commission approves use of Ameluz(R) for the treatment of actinic keratosis on extremities and trunk/neck

10.03.2020 / 16:00
The issuer is solely responsible for the content of this announcement.


European Commission approves use of Ameluz(R) for the treatment of actinic keratosis on extremities and trunk/neck

Leverkusen, Germany, March 10, 2020 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced that the European Commission has approved the use of Biofrontera's prescription drug Ameluz(R) in combination with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) on the extremities and trunk/neck. In addition, the results of the follow-up phase of the clinical study comparing daylight PDT with Ameluz(R) and Metvix(R) were included in the product information (SmPC). With a recurrence rate of 19.5%, Ameluz(R) showed lower recurrence rates after 12 months than Metvix(R) with 31.2%.

"We are very pleased about the extended label now approved for Ameluz(R) in the EU. Our outstanding results in the treatment of AK on all body regions confirm the excellent efficacy of PDT with Ameluz(R)", says Prof. Dr. Hermann Lübbert, CEO of Biofrontera AG. "We expect that the extension of the approval will further strengthen the market positioning of Ameluz(R) in Europe".

The approval of the label extension by the European Commission followed a positive opinion issued by the European Medicines Agency (EMA) (see press release dated February 3, 2020) and was based on the results of one phase III clinical trial with a total of 50 patients. The multi-center, randomized, double-blind, placebo-controlled, intra-individual study included six study centers in Germany, where patients with four to ten clinically confirmed AK lesions each in comparable areas on the right and left side of the extremities and/or trunk/neck were treated. Patients were treated with Ameluz on one randomly selected side, the other side was treated with placebo. If lesions remained on both sides of the body, the PDT was repeated three months later. The final evaluation of the patients for determination of the study's primary endpoint took place three months after the last PDT. The clinical study phase was then followed by a follow-up phase of twelve months after the last PDT, in which recurrence rates and/or numbers of new AKs and skin tumors were determined. The primary regulatory endpoint, published on March 20th, 2019, showed that Ameluz(R) was significantly superior (p<0,0001) to placebo based on its mean total lesion clearance rate of 86% compared to 33% for placebo. Significant superiority of Ameluz(R) was also demonstrated for all secondary parameters. After 12 months, the overall lesion recurrence rates were 14.1% after Ameluz(R) treatment, compared to 27.4% after placebo treatment (see press release dated January 14th, 2020).

-End-

 

Enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer
+49 (0) 214 87 63 2 0


[email protected]
IR UK: Seton Services
Toni Vallen
+44(0) 20 7729 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas

+1 646-536-7035
+1 508-280-6592

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi(TM) for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.



10.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: [email protected]
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 993739

 
End of News DGAP News Service

993739  10.03.2020 

fncls.ssp?fn=show_t_gif&application_id=993739&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 12,03 21,11 31,26 30,35 28,79 25,74 31,70
EBITDA1,2 -13,05 -17,72 -20,22 -4,70 27,95 1,87 4,20
EBITDA-Marge3 -108,48 -83,94 -64,68 -15,49 97,08 7,26
EBIT1,4 -13,93 -18,48 -23,38 -10,03 24,66 1,12 3,30
EBIT-Marge5 -115,79 -87,54 -74,79 -33,05 85,66 4,35 10,41
Jahresüberschuss1 -16,10 -9,58 -7,36 -13,02 33,86 -44,17 0,00
Netto-Marge6 -133,83 -45,38 -23,54 -42,90 117,61 -171,60 0,00
Cashflow1,7 -13,12 -13,43 -32,89 -2,85 30,44 -3,90 0,00
Ergebnis je Aktie8 -0,43 -0,20 -0,16 -0,24 0,68 -0,77 -0,08
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

INVESTOR-INFORMATIONEN
©boersengefluester.de
Biofrontera
WKN Kurs in € Einschätzung Börsenwert in Mio. €
604611 0,340 21,69
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 2,18 0,00 -1,39
KBV KCV KUV EV/EBITDA
1,07 - 0,84 11,59
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 20.06.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
31.05.2023 31.08.2023 - 27.04.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-9,81% -34,49% -15,21% -69,78%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Biofrontera AG  ISIN: DE0006046113 können Sie bei EQS abrufen


Biotechnologie , 604611 , B8F , XETR:B8F